Modecainide (BMY 40327) |
Catalog No.GC32535
One-Click Copy Product Info
|
Modecainide(BMY 40327)는 항부정맥제인 Encainide의 주요 대사 산물입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 81329-71-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Modecainide is a major metabolite of Encainide, which is an antiarrhythmic agent.
The effect of Encainide and its two major metabolites, O-demethylated Encainide (MJ 9444) and 3-O-methoxy Encainide (MJ 14030), on cardiac conduction is studied by recording His bundle potentials in isolated perfused rabbit hearts and Purkinje and muscle conduction in vivo in dog hearts after destruction of the atrioventricular node. Both metabolites are 4 to 15 times more potent than Encainide in slowing conduction through the atria, the AV-node and the His-Purkinje system of the rabbit heart. In the dog, Encainide (0.8-3.2 mg/kg i.v.) slows conduction of extrasystoles in both Purkinje and muscle at all coupling intervals, increases the effective refractory period and the functional refractory period of the Purkinje pathway. MJ 9444 (0.05-0.4 mg/kg) speeds Purkinje conduction of early (less than 300 msec) without affecting or while slowing conduction of late (greater than 350 msec) extrasystoles. Higher doses (0.4-1.6 mg/kg) slows conduction at all intervals. The effective refractory period and the functional refractory period are decreased but in some cases returned to control values at the higher doses. Muscle conduction is slowed at doses of 0.4 mg/kg or more. MJ 14030 (0.05-3.2 mg/kg) has variable effects, behaving like MJ 9444 in three experiments but like the parent compound in two others[1].
[1]. Dresel PE. Effect of encainide and its two major metabolites on cardiac conduction. J Pharmacol Exp Ther. 1984 Jan;228(1):180-6.
| Cas No. | 81329-71-7 | SDF | |
| Canonical SMILES | O=C(NC1=CC=CC=C1CCC2N(C)CCCC2)C3=CC=C(O)C(OC)=C3 | ||
| Formula | C22H28N2O3 | M.Wt | 368.47 |
| Solubility | Methanol : ≥ 250 mg/mL (678.48 mM); DMSO : 100 mg/mL (271.39 mM; Need ultrasonic) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7139 mL | 13.5696 mL | 27.1393 mL |
| 5 mM | 542.8 μL | 2.7139 mL | 5.4279 mL |
| 10 mM | 271.4 μL | 1.357 mL | 2.7139 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)